Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.1 (
pyruvate carboxylase
)
1,516
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Within 2 h after glucose administration to fasting rats the incorporation of radioactive lactate into blood glucose and liver glycogen is decreased. Using tryptophan, which facilitates the study of gluconeogenesis prior to the phosphoenolpyruvate (PEP) carboxykinase step by increasing the level of certain hepatic metabolites, we have found that in animals fasted for 24 h glucose markedly decreased hepatic malate and aspartate concentrations without a corresponding fall in that of pyruvate, suggesting a decrease in
pyruvate carboxylase
activity. An inhibitor of fatty acid oxidation, 4-pentenoic acid, similarly decreased the accumulation of these intermediates, and
octanoic acid
significantly lessened the fall in malate and aspartate with glucose. The changes in tissue metabolite levels were consistent with inhibition of the liver
pyruvate carboxylase
reaction by glucose treatment, and with abolition of this inhibition by octanoate administration. Alanine and glutamate levels in the liver of tryptophan-treated animals were decreased 90 and 32%, respectively, by glucose. Thus, glucose administration in the whole animal acutely decreases gluconeogenesis by apparently inhibiting the
pyruvate carboxylase
step and decreasing alanine levels in the liver.
...
PMID:Acute suppression of hepatic gluconeogenesis by glucose in the intact animal. 121 89